BIOMAT Database Logo BIOMAT Database Logo

Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. 2003

Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Center for Comparative Medicine, University of California, Davis 95616, USA.

The methionine-to-valine mutation in codon 184 (M184V) in reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) or simian immunodeficiency virus (SIV) confers resistance to (-)-2'-deoxy-3'-thiacytidine (3TC; lamivudine) and increased sensitivity to 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir). We have used the SIV model to evaluate the effect of the M184V mutation on the emergence of resistance to the combination of 3TC plus PMPA. A site-directed mutant of SIVmac239 containing M184V (SIVmac239-184V) was used to select for resistance to both 3TC and PMPA by serial passage in the presence of increasing concentrations of both drugs. Under these selection conditions, the M184V mutation reverted in the majority of the selections. Variants resistant to both drugs were found to have the lysine-to-arginine mutation at codon 65 (K65R), which has previously been associated with resistance to PMPA in both SIV and HIV. Similarly, in rhesus macaques infected with SIVmac239-184V for 46 weeks and treated daily with (-)-2'-deoxy-5-fluoro-3'-thiacytidine [(-)-FTC], there was no reversion of M184V, but this mutation reverted to 184 M in all three animals within 24 weeks of treatment with (-)-FTC and PMPA. Although the addition of PMPA to the (-)-FTC therapy induced a decrease in virus loads in plasma, these loads eventually returned to pre-PMPA levels in each case. All animals receiving this combination developed the K65R mutation. These results demonstrate that the combination of PMPA with 3TC or (-)-FTC selects for the K65R mutation and against the M184V mutation in SIV RT.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D017931 DNA Primers Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques. DNA Primer,Oligodeoxyribonucleotide Primer,Oligodeoxyribonucleotide Primers,Oligonucleotide Primer,Oligonucleotide Primers,Primer, DNA,Primer, Oligodeoxyribonucleotide,Primer, Oligonucleotide,Primers, DNA,Primers, Oligodeoxyribonucleotide,Primers, Oligonucleotide

Related Publications

Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.
September 2002, Journal of virology,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.
June 2002, Journal of virology,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.
July 2002, Antimicrobial agents and chemotherapy,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.
November 2003, Antimicrobial agents and chemotherapy,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in Rhesus monkeys.
November 2001, The Journal of infectious diseases,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.
November 2003, Clinical and diagnostic laboratory immunology,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
January 1999, The Journal of infectious diseases,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
April 2004, Antimicrobial agents and chemotherapy,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
Simian immunodeficiency virus reverse transcriptase. Purification and partial characterization.
August 1990, European journal of biochemistry,
Jeffrey P Murry, and Joanne Higgins, and Timothy B Matthews, and Victoria Y Huang, and Koen K A Van Rompay, and Niels C Pedersen, and Thomas W North
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
April 2000, Journal of virology,
Copied contents to your clipboard!